Scancell Holdings plc, (PLUS:SCLP), the developer of therapeutic cancer vaccines, announces its final results for the year ended 30 April 2010.

Highlights:

• Strong progress in the development of the Company’s lead therapeutic melanoma vaccine SCIB1
• Successful fundraising of £2.54 million (gross) during 2010
• Loss before tax for the year of £1.80 million (2009: £0.8 million)
• Cash at year end of £2.83 million
• Since the year end the Company commenced Phase I/IIa clinical trials in humans for SCIB1

The Directors of the issuer accept responsibility for this announcement.

For further information contact:

Professor Lindy Durrant, (CEO)  -  Scancell Holdings Plc:

• +44 (0)207 245 1100

John Bick/Kirsty Corcoran  -  Hansard Communications

• +44 (0)207 245 1100
• +44 (0)7872 061 007

Ross Andrews/Tom Rowley  -  Zeus Capital

• +44 (0)161 831 1512

View the full document